食管癌新辅助治疗的发展与展望OA
Current Status and Prospects of Neoadjuvant Therapy for Esophageal Cancer
局部晚期食管癌目前仍以手术治疗为首选,但单一手术的疗效欠佳.新辅助治疗在毒副作用可控的前提下,可显著延长患者的长期生存,这使得新辅助治疗后行手术逐渐成为局部晚期食管癌的标准治疗方式.由于新辅助治疗的治疗模式多样、用药方案多变,且不断更替重组,因此,本文就其发展历程和现状进行梳理与总结.
In the management of patients with locally advanced esophageal cancer,surgical intervention remains the primary treatment option.Nonetheless,prior studies indicate that the efficacy of isolated surgical procedures is limited.The advent of neoadjuvant therapy has led to research demonstrating a significant prolongation of long-term survival in patients,accompanied by manageable side effects.Consequently,surgery following neoadjuvant therapy has become the standard approach for treating locally advanced esophageal cancer.The modalities of neoadjuvant therapy are varied,with the pharmacological agents employed in treatment being subject to continuous replacement and recombination.Therefore,this article aims to review and summarize the advancements in neoadjuvant therapy for esophageal cancer.
赵恺欣;聂新明;韩泳涛
西南医科大学附属医院胸外科,四川 泸州 646000西南医科大学附属医院胸外科,四川 泸州 646000西南医科大学附属医院胸外科,四川 泸州 646000
医药卫生
食管癌围手术期治疗新辅助治疗
esophageal cancerperioperative therapyneoadjuvant therapy
《食管疾病》 2026 (3)
161-171,11
四川省科学技术厅国际科技创新合作项目(2026YFHZ0053)
评论